AMEX · Healthcare · Drug Manufacturers - Specialty & Generic · USA
cbdMD Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
cbdMD Inc is a consumer wellness company that develops, manufactures, and sells supplement brands powered by hemp-derived cannabinoids and functional ingredients. Its portfolio includes the cbdMD brand with oils and gummies, Paw CBD for pet wellness, ATRX with mushroom products, and Herbal Oasis beverages. The company distributes through direct-to-consumer e-commerce, online marketplaces, and wholesale channels to retailers and international markets.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the cbdMD Inc stock.
Overvalued: intrinsic value $0.30 per share, market price $0.36, margin of safety -21.5% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.30; the price of $0.36 is 22% above that value.
All 82 Drug Manufacturers - Specialty & Generic stocks
12 more in this industry show a wider margin of safety.
YCBD is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.30; the price of $0.36 is 22% above that value.
$0.30 per share (as of the 2026-11-17 close), against a market price of $0.36. That is a margin of safety of -21.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.